Sir, The emergence of resistance of Mycobacterium tuberculosis to fluoroquinolones in patients with newly diagnosed infection has been a concern, especially in patients who have prior exposure to fluoroquinolones. 1 Furthermore, the usage of fluoroquinolones in community-acquired infection has been reported to delay the diagnosis of tuberculosis (TB). 2, 3 The development of a new quinolone that retains the antibacterial activity spectrum of classic fluoroquinolones but with a relatively low activity against M. tuberculosis might have a role to play in removing the concern of potentially delaying the diagnosis of TB.
Nemonoxacin (TG-873870) is a non-fluorinated quinolone that is currently being developed in oral and intravenous formulations. This agent has good in vitro activities against major pathogens from respiratory tract and skin infections, including penicillin-resistant Streptococcus pneumoniae and methicillinresistant Staphylococcus aureus. This agent differs from fluoroquinolones in that it lacks the fluorine in the C6 position; the fluorine atom at C6 improves cell penetration and gyrase affinity. 4 Nemonoxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV and retains potent broad-spectrum activities against Gram-positive and -negative bacteria. 5 As there is no evidence of the topoisomerase IV gene in the genome of M. tuberculosis, gyrase appears to be the sole target for quinolones in M. tuberculosis. 4, 6 The purpose of this study was to compare the susceptibilities of M. tuberculosis isolates to nemonoxacin and classic fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin and gemifloxacin).
In total, 109 non-duplicate and consecutive TB isolates, recovered from various clinical specimens, were collected from 2000 to 2007 at the National Taiwan University Hospital (NTUH). Susceptibility to first-line anti-TB drugs, including isoniazid (0.2 and 1.0 mg/L), rifampicin (1 mg/L) and ethambutol (5 mg/L), and second-line anti-TB drugs, including streptomycin (2 and 10 mg/L), rifabutin (0.5 mg/L), ofloxacin (2 mg/L), ethionamide (5 mg/L) and para-aminosalicylic acid (2 mg/L), was determined in the Mycobacteriology Laboratory of NTUH using modified, proportional, disc elution methods. A M. tuberculosis suspension was inoculated onto Middlebrook 7H10 agar (BBL Microbiology Systems, Cockeysville, MD, USA) that contained anti-TB drugs at respective concentrations. The tested isolate was considered resistant if the proportion of the tested isolate was .1% of the control population. A multidrugresistant (MDR)-TB isolate was defined as being resistant to isoniazid (0.2 mg/L) and rifampicin (1 mg/L).
MICs of five quinolones for 66 MDR-TB isolates and 43 non-MDR-TB isolates collected from 2000 to 2007 were determined using the agar dilution method.
7 Concentrations in the range 0.03-32 mg/L were tested. The MIC of each isolate/drug pair was the lowest concentration of the agent that inhibited .99% of the growth of colonies for the drug-free control. Resistance was presumptively defined as follows: .2 mg/L for ciprofloxacin and levofloxacin; and .0.5 mg/L for moxifloxacin. 8 For gemifloxacin and nemonoxacin, no MIC interpretive criteria were available.
All of the 43 non-MDR-TB isolates were susceptible to ethambutol, rifabutin, ethionamide, para-aminosalicylic acid and ofloxacin; 30.2% of the non-MDR-TB isolates were resistant to streptomycin. The rates of resistance to ethambutol, streptomycin, rifabutin, ethionamide, para-aminosalicylic acid and ofloxacin for MDR-TB were 66.7%, 40.9%, 56.1%, 12.1%, 12.1% and 15.5%, respectively.
The MIC distribution and MICs at which 50% (MIC 50 ) and 90% (MIC 90 ) of the isolates were inhibited for the 66 MDR-TB and 43 non-MDR-TB isolates are shown in Table 1 . The MICs of the tested quinolones for both non-MDR-TB and MDR-TB isolates were in the order of moxifloxacin , levofloxacin , ciprofloxacin , nemonoxacin ¼ gemifloxacin. For non-MDR-TB isolates, the rates of susceptibility to levofloxacin, ciprofloxacin and moxifloxacin were 100%, 95.3% and 86%, respectively. For MDR-TB isolates, the rates of susceptibility to levofloxacin, ciprofloxacin and moxifloxacin were 62.1%, 50% and 60.6%, respectively. Notably, the MIC 90 s of the five quinolones for MDR-TB isolates were at least 4 times higher than the MIC 90 s for non-MDR-TB isolates. Among the five quinolones tested, levofloxacin and moxifloxacin had the lowest MICs for M. tuberculosis; in most cases, the levofloxacin and moxifloxacin MICs were at least 16 times lower than those of nemonoxacin. The MIC 90 s of nemonoxacin and gemifloxacin for non-MDR-TB isolates in this study were 16 mg/L. Nine isolates that were resistant to all four classic quinolones (ofloxacin, ciprofloxacin, moxifloxacin and levofloxacin) had both nemonoxacin and gemifloxacin MICs of .32 mg/L.
Our findings are consistent with previous reports 9, 10 and suggest that moxifloxacin and levofloxacin may be suitable alternative agents, or even candidates for use as new first-line agents, in patients with non-MDR-TB infections. Among patients with MDR-TB isolates, fluoroquinolone susceptibility should be routinely evaluated to cautiously select appropriate antimicrobial agents in Taiwan or other areas with a high fluoroquinolone resistance rate.
Controversy exists as to whether the usage of quinolones, with good anti-TB activity, in community-acquired pneumonia delays the diagnosis of TB, particularly in areas with a high endemicity of TB. 2, 3 With their low activity against M. tuberculosis, nemonoxacin and gemifloxacin are likely to have the least potential to mask and delay the diagnosis of TB.
In conclusion, the high resistance rate of MDR-TB to both first-and second-line anti-TB agents remains a therapeutic challenge in Taiwan, and more effective TB control interventions and potent anti-TB agents are urgently needed. The higher MICs of nemonoxacin and gemifloxacin for non-MDR-TB and MDR-TB isolates indicates the limited role of these two agents in the treatment of TB. The potential role of nemonoxacin and gemifloxacin in treating community-acquired pneumonia without masking and delaying the diagnosis of TB requires further study.
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